Back to search results

Registry for Triple Negative Breast Cancer and Hereditary Breast and Ovarian Cancer

This study is a registry for people with Triple Negative Breast Cancer (TNBC) or those who carry certain genetic mutations (changes in genes like BRCA1 or BRCA2) that increase cancer risk. The goal is to collect information to better understand how these genetic changes are linked to cancer outcomes in TNBC. Researchers will look at how common these genetic mutations are in people with TNBC, what helps predict how well people respond to chemotherapy, and how long people live after treatment. You can join if you have TNBC (stages I-IV, diagnosed within the last 5 years) or if you have a known genetic mutation. This is an observational study, meaning researchers will collect information without giving you any specific treatments.

Study design
This is an observational study, meaning researchers will collect information without providing specific treatments. The study plans to enroll 1500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track the prevalence of genetic mutations and predictors of chemotherapy response for 5 years. They will also follow long-term survival rates for 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02302742

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Recruiting
Not specifiedAll AgesObservational
University of Kansas Medical Center
~3,000 participants
Updated 2026-08-18 on ClinicalTrials.gov

At a glance

Recruiting sites
11 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of germline mutations (such as BRCA1/2 mutations) in patients with TNBC
Measured over 5 years
+2 more outcomes measured

Conditions

Breast Cancer
Hereditary Breast and Ovarian Cancer

Explore related trials

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeBreast CarcinomaBRCA Gene FamilyESR1 GenePartner and Localizer of BRCA2PGR GenePTEN GeneTP53 Gene

Where it's being run

11 sites across 2 states
Kansas6
Missouri5

Study leadership

  • Priyanka Sharma, MD · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

Joshua Staley
[email protected]
913-588-8548
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

ER/PR \<10% and HER negative per current ASCO/CAP guidelines
Stages I-IV
Any age at diagnosis
Patient must be within 5 years of diagnosis
Eligible regardless of genetic testing status
Genetic testing recommended for patients meeting NCCN and Medicare guidelines
Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer
Healthy patients harboring mutations also eligible
There is no time limit from the time of diagnosis of cancer and enrollment.
Eligible regardless of personal history of cancer

Exclusion

Patient only carries a HBOC mutation that is classified as "polymorphism" of "favor polymorphism"

What this trial measures

  • Prevalence of germline mutations (such as BRCA1/2 mutations) in patients with TNBC5 years
  • . Predictors of response to neo/adjuvant chemotherapy in patients with TNBC5 years
  • Long term Disease free and overall survival rates in TNBC patients treated with different systemic therapies10 years